Highest-materiality recent filing
Vertex to acquire Crinetics Pharmaceuticals for $85.00 per share in cash; expected close Q3 2026
Vertex to acquire Crinetics for $85.00 per share in cash; expected to close in Q3 2026.
All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
Total revenue $2.99B, up 8% vs Q1 2025; GAAP net income $1.0B, non-GAAP $1.1B.
Vertex director Suketu Upadhyay to depart after annual meeting to become Incyte CFO
Upadhyay will not stand for re-election due to scheduling conflicts from his incoming CFO role at Incyte.
Vertex completes BLA submission for povetacicept in IgAN with priority review
Submitted rolling Biologics Licensing Application to FDA for povetacicept to treat IgAN in adults.
Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B
FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.
Vertex Q3 rev $3.08B (+11% YoY), FY guidance refined; povetacicept IgAN BLA on track
Q3 total revenue $3.08B (+11% vs Q3 2024); GAAP net income $1.1B, non-GAAP $1.2B.
Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed
Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B
Vertex Pharmaceuticals authorizes $4.0B share repurchase program
Board authorized new $4.0B stock repurchase program (2025 Repurchase Program) with no expiration date.
Vertex shareholders elect all 11 directors, reject golden parachute proposal at 2025 annual meeting
All 11 director nominees elected with majority support; Bruce Sachs received lowest 'for' votes at 211.6M.
Revenue $2.77B, +3% YoY; US revenue +9% to $1.66B, ex-US -5% to $1.11B due to Russia IP violation.
Vertex halts VX-264 type 1 diabetes program; expects ~$400M impairment charge
Phase 1/2 trial of VX-264 for type 1 diabetes fails; program will not advance further.
Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.
Vertex receives FDA approval for new CF drug ALYFTREK; wholesale cost $370K/year
FDA approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for CF in patients 6+ years with at least one F508del mutation.
Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B
GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.
Vertex extends Boston headquarters leases to 2044, adding renewal options
Extended combined ~1.1 million sq ft of office and lab space under two leases in Boston.
Vertex Q2 product revenue $2.65B (+6% YoY); raises FY 2024 guidance to $10.65-10.85B
GAAP net loss of $3.6B in Q2 due to $4.4B AIPR&D charge from Alpine acquisition.
Vertex expects $4.4B AIPR&D charge and $200M compensation expense from Alpine acquisition in Q2 2024
Vertex records one-time non-deductible AIPR&D expense of approx. $4.4B in Q2 2024 from Alpine asset acquisition accounting.
Vertex completes $5.0B acquisition of Alpine Immune Sciences on May 20, 2024
Acquisition of Alpine for approximately $5.0B in equity value completed.
Vertex Pharmaceuticals Shareholders Elect Directors and Approve Proposals at Annual Meeting
Shareholders elected all 11 board nominees, including Reshma Kewalramani and Jeffrey Leiden, with each receiving over 217 million votes for.
Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition
Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.
Vertex to acquire Alpine Immune Sciences for $65 per share in all-cash tender offer
Vertex agrees to buy Alpine Immune Sciences at $65/share via tender offer followed by a merger.
FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).
FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price
On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
Vertex appoints Nancy Thornberry to board of directors
Nancy Thornberry, former CEO of Kallyope and ex-Merck executive, joins the board effective December 5, 2023.
Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B
Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).
Vertex appoints Michel Lagarde to board as tenth director
Michel Lagarde appointed to Vertex board effective Oct 5, 2023; board expands to 10.
Vertex Q2 product revenue $2.49B (+14% YoY); raises FY 2023 guidance to $9.7-9.8B
Q2 product revenue $2.49B, up 14% vs Q2 2022; U.S. revenue $1.51B (+7%), OUS $985M (+26%).
Vertex shareholders elect all nine director nominees at 2023 annual meeting
All nine director nominees elected; votes ranged from 203.8M to 223.0M in favor.
Vertex Q1 product rev $2.37B (+13%); net income down 8% on higher R&D; FY23 guidance unchanged
Product revenue $2.37B (+13% YoY); U.S. $1.40B (+3%), ex-U.S. $971M (+33%).
Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B
Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.
Vertex Q3 product revenue $2.33B (+18% YoY); raises FY22 guidance to $8.8-8.9B
Product revenue $2.334B, up 18% from Q3 2021; TRIKAFTA/KAFTRIO contributed $2.011B.
Vertex Q2 product revenue $2.20B (+22% YoY); raises FY2022 guidance to $8.6-$8.8B
Product revenues $2.20B, up 22% YoY; TRIKAFTA/KAFTRIO contributed $1.893B.
Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880
Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.
Vertex enters new $500M senior unsecured revolving credit facility, replaces 2019 agreement
$500M revolving facility, matures July 1, 2027; capacity can be increased by an additional $500M.
Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million
Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.
Vertex shareholders elect 11 directors, approve stock plan amendment adding 13.5M shares
All 11 director nominees elected, with Reshma Kewalramani receiving 218.7M votes for.
Vertex Q1 product revenue $2.10B (+22% YoY); reiterates FY 2022 guidance $8.4-8.6B
Product revenues $2.10B (+22% YoY); TRIKAFTA $1.76B (+48% YoY).
Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B
Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.
Vertex Q3 revenue $1.98B (+29% YoY); raises FY2021 guidance to $7.4-7.5B
Product revenues of $1.984B (+29% YoY); GAAP diluted EPS $3.28, Non-GAAP $3.56.
Vertex Q2 product revenues $1.79B (+18% YoY); raises FY 2021 guidance to $7.2-7.4B
Product revenues $1.793B, up 18% YoY; TRIKAFTA/KAFTRIO $1.256B led growth.
Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the "2026 Annual Meeting").
the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company
The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company
On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.
On December 5, 2023, Nancy Thornberry was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”).
On October 3, 2023, Michel Lagarde was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”), effective on October 5, 2023.
Max materiality 0.90 · Median 0.75 · Most common event earnings